| Name | Title | Contact Details |
|---|
CenterCare Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Decisions (www.HealthDec.com) is a global clinical research organization (CRO) committed to helping drug and device companies achieve greater success. Our sponsors rely on us to help them prove the value of their pipelines both faster and with the smartest possible allocation of funds. Through Agile Clinical Development- a strategic combination of adaptive design and adaptive operations Health Decisions optimizes every facet of clinical research from design protocol to the most detailed day-to-day management, so sponsors can make the most of competitive market opportunities.
ACS EDI Gateway is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marpai helps people live better, stay stronger, and spend less on healthcare by using the most advanced artificial intelligence capabilities to empower greater health outcomes and reduced costs. We bring the world`s first SMART Health Plan Services System which enables health plan members to do things they could never do before. Avert and reduce chronic illness and costly procedures with early intervention. Save money with top quality in-network providers and telehealth. Simplify complex care with experts that guide the best journey. Avoid unnecessary ER visits, procedures and re-admissions. And, use the Marpai SMART app to book appointments, access telehealth, save money and more.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.